DeLong's test for two correlated ROC curves
Z=-0.163, p=0.871
Model: Three-months clinical response –Helios+Tregs at pretreatment
Optimal Cut-off value: 34.3
AUC: 0.741(0.582-0.901), p<0.001
Model: Three-months clinical response – KIR2DL2/DL3+NKs at pretreatment
Optimal Cut-off value: 35.3
AUC: 0.724(0.581-0.866), p<0.001

Supplementary Figure S8. .632+ cross validation bootstrap ROC curves and the optimum pretreatment cut-off values of KIR2DL2/DL3+NKs and Helios+Tregs to determine the outcome of REV patients. The blue curve represents the ROC curve derived by selected cut-off point of 35.3 on the baseline level of KIR2DL2/DL3+NKs, with AUC estimated by .632+ cross validation equal to 0.724 (95%CI: 0.581-0.866) and p<0.001. Red curve represents the ROC curve derived by selected cut-off point of 34.3 on the pretreatment level of Helios+Tregs, with AUC estimated by .632+ cross validation equal to 0.741 (95%CI: 0.582-0.901) and p<0.001. Additionally, a DeLong's test statistics of the difference between ROC curves was performed with a not statistically significant result (p=0.871).